EVALUATION OF THE ROLE OF THE RELATIONSHIP OF INFLAMMATORY CYTOKINES WITH THE NEOANGIOGENESIS FACTOR IN THE DEVELOPMENT OF PROLIFERATIVE DIABETIC RETINOPATHY

Authors:

Abstract:

A clinical and immunological study was carried out in two groups of patients with diabetes mellitus at the National Center of Ophthalmology named after Academician Zarifa Aliyeva. The first group – 40 patients with non-proliferative diabetic retinopathy; the second group – 42 patients with the development of proliferative diabetic retinopathy within a year. In the first group, there was a significant decrease in inflammatory cytokines and VEGF factor at the local level (VEGF, TNF-α, IL-1β – p=0.001; IL-8 – p<0.001). Diabetic maculopathy and proliferative diabetic retinopathy developed against the background of worsening of the HbA1c diabetes compensation index (9.7±1.1 %; p<0.001) with an increase in angiogenesis factor VEGF and inflammatory cytokines in the blood (VEGF – p=0.034; TNF-α, IL-1β – p=0.001; IL-8 – p<0.001) and tear fluid (VEGF – p=0.018; TNF-α – p=0.005; IL-1β, IL-8 – p<0.001). At the same time, a positive correlation was revealed between the local and systemic levels of VEGF (r=0.333; p=0.031), between the central thickness of the macula and HbA1c, VEGF, TNF-α, IL-1β, IL-8 of a high degree of significance (p<0.001). The results indicate the advisability of a detailed study of the issue of preventive anti-inflammatory therapy along with antiangiogenic treatment for diabetic retinopathy.

Keywords:

diabetic retinopathy glycosylated hemoglobin vascular endothelial growth factor cytokines inflammation

References:

1. Kasimov EM, Kazimova BX, Shakhmaliyeva AM. Vliyaniye antiangiogennoy terapii na morfologicheskiye i funktsionalnyye parametry glaza pri razlichnykh stadiyakh diabeticheskoy retinopatii u bolnykh sakharnym diabetom 2-go tipa. Azerbaijan Journal of Ophthalmology. 2013; 3(13): 31­37. [in Russian]
2. Pera-Vasylchenko AV, Ryadnova VV, Voskresenska LK, Bezkorovayna IM, Bezega НМ. Patomorfolohichni zminy intrakranialnoho viddilu zorovoho nerva pry tsukrovomu diabeti. Svit medytsyny ta biolohiyi. 2021; 1(75): 201–205. doi: 10.26724/2079–8334–2021–1–75–201–205. [in Ukrainian]
3. Costagliola C, Romano V, De Tollis M, Aceto F, dell′Omo R, Romano MR et al. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013; 2013: 629529. doi: 10.1155/2013/629529.
4. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020; 37: 101799. doi: 10.1016/j.redox.2020.101799.
5. Mason RH, Minaker SA, Lahaie Luna G, Bapat P, Farahvash A, Garg A. et al. Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. Eye (Lond). 2022 Jun 7. doi: 10.1038/s41433-022-02127-x.
6. Matheus ASM, da Matta MFB, Clemente ELS, Rodrigues MLG, Valença DCT, Drummond KRG et al. Biochemical and clinical markers of endothelial dysfunction do not outweigh traditional risk factors for the presence of diabetic retinopathy in patients with type 1 diabetes. Diabetol Metab Syndr. 2022; 14(1): 141. doi: 10.1186/s13098-022-00912-y.
7. Palenski TL, Sorenson CM, Sheibani N. Inflammatory cytokine-specific alterations in retinal endothelial cell function. Microvasc Res. 2013; 89: 57–69. doi: 10.1016/j.mvr.2013.06.007.
8. Sirman YaV, Savytskyi IV. Changes in endothelial nitric oxide synthase activity over time after induction of experimental diabetic retinopathy. Journal of Ophthalmology (Ukraine). 2020; 0(6): 44–54. doi: 10.31288/oftalmolzh202064454.
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047–1053. doi: 10.2337/diacare.27.5.1047.
10. Yenihayat F, Özkan B, Kasap M, Karabaş VL, Güzel N, Akpınar G et al. Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol. 2019; 39(4): 821–828. doi: 10.1007/s10792-018-0874-6.
11. Zhang D, Lv FL, Wang GH. Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci. 2018; 22(16): 5071–5076. doi: 10.26355/eurrev_201808_15699.

Publication:

«World of Medicine and Biology» Vol. 19 No. 85 (2023) , с. 148-152
УДК 617.735-002-02:616.379-008.64

DOI:

https://doi.org/10.26724/2079-8334-2023-3-85-148-152